The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of anti-transforming growth factor-beta (TGFß) monoclonal antibody GC1008 in relapsed malignant pleural mesothelioma (MPM).
James Stevenson
No relevant relationships to disclose
Hedy Lee Kindler
Research Funding - Genzyme
Daniel Schwed
No relevant relationships to disclose
Anjana Ranganathan
No relevant relationships to disclose
Mona Jacobs-Small
No relevant relationships to disclose
Jennfier Shouldis
No relevant relationships to disclose
Amy Marshall
No relevant relationships to disclose
Daniel Heitjan
No relevant relationships to disclose
Corey J. Langer
No relevant relationships to disclose
Frank James Hsu
Employment or Leadership Position - Genzyme
Stock Ownership - Genzyme
Steven Albelda
Research Funding - Genzyme